Abstract
Lung adenocarcinoma is the leading cause of cancer death. To characterize the tumor microenvironment (TME) of early-stage lung adenocarcinoma, we performed RNA-seq profiling on 59 pairs of minimally invasive adenocarcinoma (MIA) tumors and matched adjacent normal lung tissues from Chinese patients. We observed mucin over-expression and glycosylation, and altered cytokine-cytokine interactions in MIA tumors, which also had distinct adaptive immune TME of higher CD4+ T cell infiltration, higher plasma B cell activation, and lower CD8+ T cell infiltration. The high expression of markers for B cells, activated CD4 T cells, and follicular helper T (Tfh) cells in MIA implicated the formation of tertiary lymphoid structures (TLS), which were supported by two independent single-cell RNA-seq data. Multiplex immunohistochemistry (mIHC) staining of 22 MIA tumors validated TLS formation and revealed an enrichment of follicular regulatory T cells (Tfr) in TLS follicles, which may explain the lower CD8+ T cell infiltration and attenuated anti-tumor immunity in MIA.
Significance We discovered a potential immunosuppressive phenotype in MIA mediated by follicular regulatory T cells (Tfr) in TLS formation, which could be a potential mechanism of CD8+ T cell exclusion. Our study demonstrated how integrating tumor transcriptome and pathology can characterize the TME and elucidate potential mechanisms of tumor immune evasion.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Our bulk RNA-seq data is not from clinical trial
Funding Statement
National Natural Science Foundation of China (Grant No.81872290, 81972172, and 81772763),the Shanghai Science and Technology Committee (No. 19XD1423200, 18140903900).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of Shanghai Pulmonary Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos